Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group

Lena Weiss(LMU Klinikum), Michael Haas(Harvard University), Frank Gieseler(University Hospital Schleswig-Holstein), D. Quietzsch(Klinikum Chemnitz), Volker Heinemann(LMU Klinikum), Stefan Boeck(German Cancer Research Center), Anke Reinacher‐Schick(Ruhr University Bochum), Thomas Hoehler(Johannes Gutenberg University Mainz), Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), C. Benedikt Westphalen(LMU Klinikum), D. Zhang(LMU Klinikum), Jens T. Siveke(German Cancer Research Center), Ulrich Kaiser(University of Applied Sciences Landshut), Klara Dorman(LMU Klinikum), Laura Fischer(LMU Klinikum), Michael Schenk(Krankenhaus Barmherzige Brüder), G. Seipelt, Dirk Waldschmidt, Julia Mayerle(LMU Klinikum)
ESMO Open
March 18, 2024
10.1016/j.esmoop.2024.102944
Cited by 3

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Cohort Profile: The Study of Health in Pomerania
|International Journal of Epidemiology|2010|1k